MARKET

VYNT

VYNT

Vyant Bio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.020
-0.160
-3.83%
After Hours: 3.960 -0.06 -1.49% 19:37 04/09 EDT
OPEN
4.130
PREV CLOSE
4.180
HIGH
4.320
LOW
3.940
VOLUME
619.12K
TURNOVER
--
52 WEEK HIGH
17.50
52 WEEK LOW
2.108
MARKET CAP
44.25M
P/E (TTM)
-1.3308
1D
5D
1M
3M
1Y
5Y
Vyant Bio Announces Newly Appointed Board of Directors
GlobeNewswire · 5d ago
Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX
Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners as ...
GlobeNewswire · 04/01 21:45
News On Cancer Genetics Inc. (CGIX) Now Under VYNT
News On Cancer Genetics Inc. (CGIX) Now Under VYNT
Dow Jones · 03/31 21:08
Global Colorectal Cancer Diagnostics Market is Anticipated to Exhibit an Impressive Expansion at a CAGR of 8.5% by 2022 | Sysmex Corporation, Cancer Genetics
Mar 28, 2021 (MARKITWIRED via COMTEX) -- The global colorectal cancer diagnostics market is anticipated to exhibit an impressive expansion at a CAGR of 8.5%...
Markitwired · 03/29 02:05
Prostate Cancer Diagnostics Market: PSA Tests will Continue to be the Largest Adopted Tests for Diagnosis with Keyplayers Abbott Laboratories, AstraZeneca plc.
Mar 28, 2021 (MARKITWIRED via COMTEX) -- According to the latest report by Fact.MR, the global prostate cancer diagnostics market is anticipated to exhibit a...
Markitwired · 03/28 19:03
Flow Cytometry Market -2026 | With CAGR 8.30% |Revenue, Industry Growing Demand, Size, Share, Business Opportunities, Top Companies, Regional Outlook
Japan, Japan, Fri, 26 Mar 2021 07:05:36 / Comserve Inc. / -- Flow Cytometry Market With Top Countries Data, Industry Analysis, Size, Share, Revenue,...
Comserve · 03/26 11:07
Mid-Day Market Update: Crude Oil Down Over 4%; Cellect Biotechnology Shares Surge
Midway through trading Thursday, the Dow traded down 1% to 32,096.94 while the NASDAQ fell 1.28% to 12,796.15. The S&P also fell, dropping 0.89% to 3,854.71.
Benzinga · 03/25 16:08
8-K: CANCER GENETICS, INC
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/25 15:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VYNT. Analyze the recent business situations of Vyant Bio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VYNT stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 3.78M
% Owned: 34.31%
Shares Outstanding: 11.01M
TypeInstitutionsShares
Increased
4
85.03K
New
3
40.16K
Decreased
2
37
Sold Out
2
1.00K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+0.74%
Healthcare Providers & Services
+2.05%
Key Executives
Chairman/Director
John Fletcher
President/Chief Executive Officer/Chief Financial Officer/Chief Accounting Officer/Director
John Roberts
Chief Financial Officer
Glenn Miles
President
Ralf Brandt
Executive Vice President
William Finger
Other
Michael McCartney
Director
Marcus Boehm
Director
Paul Hansen
Director
Joanna Horobin
Director
Yung-Ping Yeh
Independent Director
Geoffrey Harris
Independent Director
Howard McLeod
No Data
About VYNT
Vyant Bio, Inc., formerly Cancer Genetics, Inc., operates through its subsidiaries, vivoPharm, Pty Ltd. (vivoPharm) and StemoniX, Inc. (StemoniX). vivoPharm offers preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. It is focused on precision and translational medicine to drive drug discovery and therapies. vivoPharm specializes in conducting studies to guide drug discovery and development programs with in oncology and immuno-oncology. StemoniX develops and manufactures human induced pluripotent stem cell (iPSC) based neural, cardiac and pancreatic screening platforms for drug discovery and development. It is engaged in allowing the discovery of new medicines through human biology and software technologies.

Webull offers kinds of Vyant Bio Inc stock information, including NASDAQ:VYNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYNT stock methods without spending real money on the virtual paper trading platform.